Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AITX Participates in Its Fourth TV & Film Production with More Expected
https://www.globenewswire.com/news-release/2022/06/13/2461262/0/en/AITX-s-Subsidiary-Robotic-Assistance-Devices-Participates-in-Its-Fourth-TV-Film-Production-with-More-Expected.html
$AGYP @ .15 on watch! Oil prices holding strong in the $120 range. PM chart >>
https://alliedengycorp.com/
$PVSP Update: "Hello PVSP shareholders: Congratulations Transcendence Age Corp. team on being chosen to design and plan the buildout of the largest CBD farm to ever be constructed in the world. Good luck on your meetings in Denver this week. Thank you shareholders for your support."
Hello PVSP shareholders: Congratulations Transcendence Age Corp. team on being chosen to design and plan the buildout of the largest CBD farm to ever be constructed in the world. Good luck on your meetings in Denver this week. Thank you shareholders for your support.
— Pervasip Corp (@PervasipC) March 22, 2021
NEWYY..........................................https://stockcharts.com/h-sc/ui?s=NEWYY&p=D&yr=0&mn=2&dy=12&id=p84071410134
$AGYP Financial Times Article goes into detail on the coming surge in Oil prices in the future! >>
The world must brace itself for a further surge in oil prices
$AGYP massively undervalued play with confirmed oil production and sales.
SFLMaven Corp. - $SFLM's CEO Joseph Ladin was interviewed by MoneyTV for an in-depth overview.
In the interview, Ladin discussed the Company’s strong sales performance so far in 2022, highlighting results that include nearly $5 million in year-to-date sales, up 19% year over year, with 4% growth in average sales price, 15% growth in items sold, and 17% growth in repeat buyers, showing strong retention and customer satisfaction.
Ladin also highlighted the Company’s recent launch of the world’s first native virtual dealership of high-end vintage digital jewelry NFT items for avatar use in the metaverse.
https://finance.yahoo.com/news/sflmaven-ceo-joe-ladin-joins-123000109.html
$PVSP utilize project management to translate, plan, and execute strategies to help achieve successful submissions, adhere to agency compliance, and remediate identified issues.
$PVSP With over 200,000 square feet of grow facility space under management, supporting a 30-person distribution center, and licensing the Artizen™ brand to cultivators in Washington State, ZAM is poised to expand its reach across the West coast and into Arizona and other recreational states.
GTVH big acquisition, small float, low marketcap trading like 10x under book vlaue with revenue
$PVSP Pervasip owns 100% of Artizen Corporation (“Artizen Corp”). Artizen Corp’s wholly owned subsidiary, Zen Asset Management LLC (“ZAM”) is a foundational operator that provides the basis for our cannabis related investments. ZAM, a diversified asset management company was founded to acquire, develop, and support companies and technologies in the cannabis industry.
$AGYP 13-week high for Oil on rising U.S. gasoline demand! Seems to be no end in site for rising Oil prices as countries raise supply concerns and as demand increases! >>
$GTCH the company is developing Gate-All-Around FET (GAA FET) support for its integrated circuits, productivity enhancement EDA technology. The support for the Gate-All-Around FET device will be added to all GBT’s EDA tools, starting with its interactive, advice and correction of design rule violations software. This tool works on Integrated Circuit (IC) layout data, checking manufacturing geometrical and electrical design rules correctness during the construction of an IC layout, thus creating Rule-Aware mask design environment. As the microchip’s industry is accelerating towards the new 5nm and 3nm processes, vast amount of design and manufacturing efforts are invested in the next generation; 2nm node and beyond. Foundries and major chip design firms are facing numerous challenges as well as upcoming crucial uncertainties. The traditional FinFet device is planned to be replaced, starting at 3nm, by a new promising device called the ‘Gate-All-Around FET’ device. This innovative device is considered to be a superior CMOS device in terms of conductivity, scaling, and electrical characteristics. GAA FET’s performance is expected to be significantly improved, with the goal of power consumption reduction, which makes it attractive for IC design companies to stay ahead of the domain’s competition. GBT’s visual, design rule detection and correction program is operating on an IC layout database, identifying violations, and performing the necessary correction, ensuring a correct-by-construction IC design environment. This approach could save significant amount of the global project’s design time by early identification and elimination of design’s violations and flaws. GBT believes that by adding GAA FET support, design time could be reduced especially with advanced upcoming nanometer chips of 2nm and beyond. GBT plans to incorporate GAA FET support within all its EDA software tools in order to remain at the forefront of the IC design arena.
"Fundamentally, today’s advanced chips are having smaller devices with smaller geometries. The silicon areas become more compact and crowded which impacts performance, power consumption and reliability. GAA FET technology is expected to provide performance enhancement with lower power consumption, which we believe makes it attractive for design firms. Another important aspect is that GAA FET relaxes some of the problems introduced by the traditional FinFETS. The new transistor structure is designed to provide stronger device gate control which would enable better conductivity and improved electrical characteristics. This is an important factor because at the smaller nodes, we are noticing more variability, particularly for memories. But with new technologies, typically comes uncertainty. With GAA FET we can expect higher potential for variability and design rule challenges, especially with today’s billions of transistors and advanced functionalities ICs. The ever-going demand to consume minimal power and to operate with high performance using GAA FET, could become a major obstacle for design firms, delaying milestones and timelines. GBT plans to develop GAA FET support for all its EDA productivity enhancement software tools with the goal of saving significant design time, enabling IC designers to maintain competitive schedules. We are going to start with our interactive identification and correction of design rule violations program. This tool operates during the construction of an IC layout, providing an on-the-fly feedback about violations. The tool also offers automatic correction of the detected violation and could save major project’s design time. Without the appropriate level of geometrical accuracy within an affordable time frame designers might need many extra months to reach the desired signoff schedule. Design Rule identification and correction process is a critical step during signoff, and without an intelligent productivity technology an enormous amount of pressure is put on designers to achieve design closure in a timely manner.
MVCO Metavesco fresh new metaverse stock, ticker and name change just on Friday
$AAGC On June 6th, 2022, Hollywood Star Cuts entered into an agreement with one of the world’s largest producers and importers of commercial Tanning Booths.
https://www.globenewswire.com/news-release/2022/06/08/2458887/0/en/Hollywood-Star-Cuts-Signs-Game-Changing-Agreement.html
$PVSP Intereactive Chart https://www.barchart.com/stocks/quotes/PVSP/interactive-chart
$GTCH Cybersecurity Solutions Becoming Pervasive as Threats Escalate https://www.investorideas.com/news/2022/defense/04040Cybersecurity.asp#.YksLnHVTdbQ.twitter
RIBT --- Food Stock Play .74 - Targets $1.20/$2.20
$AGYP ~ on watch for breakout .1526 x .162 PM. Hit over .80 last summer. Many more catalysts now to push up to new highs #Oil #Gas
https://alliedengycorp.com/
Allied Energy Corporation Continues Selling Numerous loads of Oil From Their Producing Wells Throughout April
https://www.mcapmediawire.com/allied-energy-corporation-continues-selling-numerous-loads-of-oil-from-their-producing-wells-throughout-april/
Allied Energy Execute Documents To Retire 2,480,000 Common Shares From Public Float AGYP
https://www.globenewswire.com/news-release/2022/05/05/2437103/0/en/Allied-Energy-Execute-Documents-To-Retire-2-480-000-Common-Shares-From-Public-Float.html
$SNGX News: Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
June 1, 2022 (PR Newswire)
Paper published in the Journal Structure
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the binding of its Innate Defense Regulator (IDR), dusquetide, to the p62 protein. Dusquetide has demonstrated anti-infective, anti-tumor and anti-inflammatory actions in multiple animal models by modulating the body's own innate immune system. Dusquetide previously demonstrated significant benefits in reducing the duration of severe oral mucositis (SOM) in a Phase 2 clinical trial and reduction in SOM rates in the per protocol population in a Phase 3 study. In addition to the reduction of SOM, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer (HNC). This was corroborated by more recent findings confirming dusquetide's anti-tumor activity in xenograft models of breast cancer.
Based on the biological proof of principle shown both nonclinically and clinically with dusquetide, a novel synthetic peptide that modulates the body's innate immune system, Soligenix continues to explore product opportunities, both in the reduction of oral mucositis in HNC and as a potential anti-cancer treatment. Dusquetide binds to p62 or SQSTM-1, a scaffold protein implicated in a number of intracellular signaling networks implicated in tumor cell survival, including autophagy. This recent publication elaborates on the direct interaction of dusquetide with p62, as well as some of the direct downstream consequences of that interaction, consistent with its observed anti-infective, anti-tumor and anti-inflammatory activities. This information advances the understanding of dusquetide's novel mechanism of action and supports the development of analogs related to dusquetide.
"Soligenix continues to pursue potential product opportunities with our new chemical entity dusquetide," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With the supportive data from the Phase 2 and 3 oral mucositis trials, and the nonclinical anti-tumor efficacy demonstrated, we will continue to pursue potential partnership opportunities for this novel molecule and its potential analogs."
About Dusquetide
Dusquetide (the active ingredient in SGX942) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens. It also accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- and/or radiation therapy. Preclinical efficacy and safety has been demonstrated in numerous animal disease models including mucositis, colitis, macrophage activation syndrome (MAS) as well as bacterial infections, including melioidosis. Potential anti-tumor activity has been demonstrated in in vitro and in vivo xenograft studies.
SGX942 has demonstrated safety and tolerability in a Phase 1 clinical study in 84 healthy human volunteers. Positive efficacy results were demonstrated in an exploratory Phase 2 clinical study in 111 patients with oral mucositis due to CRT for HNC, including potential long-term ancillary benefits. The Phase 3 multinational, placebo-controlled, randomized study evaluated the impact of dusquetide on the duration of SOM in 268 subjects with squamous cell carcinoma of the oral cavity and oropharynx, receiving CRT. While the Phase 3 clinical study did not achieve the required level of statistical significance (pless-than or equal to 0.05) in its primary endpoint of median duration of SOM, a clinically meaningful reduction was observed, including a statistically significant reduction in the duration of SOM in the per-protocol population (p=0.049), consistent with the findings in the Phase 2 trial.
SGX942 has received Fast Track Designation from the FDA for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in HNC patients, as well as Promising Innovative Medicine designation in the United Kingdom by the Medicines and Healthcare products Regulatory Agency for the treatment of severe oral mucositis in HNC patients receiving CRT. In addition, products containing the same active ingredient, dusquetide, have been granted Fast Track Designation as an adjunctive therapy with other antibacterial drugs, for the treatment of melioidosis and Orphan Drug Designations in the treatment of MAS and the treatment of acute radiation syndrome.
Soligenix has a strong intellectual property position in the IDR technology platform, including composition of matter for dusquetide and related analogs. Dusquetide was developed pursuant to discoveries made by Professors B. Brett Finlay, PhD and Robert Hancock, PhD of the University of British Columbia, Canada. Soligenix has received partial funding from NIH for its oral mucositis clinical studies. The Phase 2 study was supported with a Phase I SBIR grant (#R43DE024032) award, with the Phase 3 study being supported by a Phase II SBIR grant (#R44DE024032) award.
In addition, a high level review of the IDR technology platform is available here.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte(TM) (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax(R) will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax(R). Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
https://c212.net/c/img/favicon.png?sn=PH74370...2022-06-01
View original content:https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html
SOURCE Soligenix, Inc.
$AGYP ~ As WTI and Brent Crude approach new highs, AGYP as an active domestic producer of oil and gas energy is positioned well.
Allied Energy Corporation (OTC: AGYP)
https://alliedengycorp.com/
$LVVV Livewire Ergogenics Provides Update on Estrella River Farms in Paso Robles and Makana Ola Farms in Humboldt, California
https://www.globenewswire.com/news-release/2022/06/06/2456887/0/en/Livewire-Ergogenics-Provides-Update-on-Estrella-River-Farms-in-Paso-Robles-and-Makana-Ola-Farms-in-Humboldt-California.html
Endexx Corporation - EDXC announced that Endexx will be presenting at the LD Micro Invitational XII, on June 8th at 10:30 am PST on Track 4. The event is being held at the Four Seasons Westlake Village presented by SRAX.
Mr. Todd Davis, Endexx’s CEO and Chairman will present a company overview and provide details on the Company’s expansion as the Company is expanding its Mass Retail footprint and store count in the US.
Private investors and institutions can schedule a one-on-one meeting with Endexx’s management, please contact your LD Micro representative or
https://www.meetmax.com/sched/event_82067/conference_home.html
https://www.stocktitan.net/news/EDXC/endexx-to-present-at-the-ld-micro-invitational-xii-four-seasons-58gethylfe0b.html
$SWISF New to The Street Newsmax TV Announces Seven Corporate Interviews for this Week’s TV Broadcast, Sunday, June 5, 2022, Hour Slot 10-11AM ET
“Weekly Sekur Privacy & Sekur Security Segment,” interview with internet privacy expert Mr. Alain Ghiai, CEO.
https://www.globenewswire.com/news-release/2022/06/03/2456066/0/en/New-to-The-Street-Newsmax-TV-Announces-Seven-Corporate-Interviews-for-this-Week-s-TV-Broadcast-Sunday-June-5-2022-Hour-Slot-10-11AM-ET.html
$TBRIF Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
https://www.newsfilecorp.com/release/126235/Therma-Bright-Provides-Update-on-FDA-EUA-Application-Process-For-AcuVidTM-COVID19-Rapid-Antigen-Saliva-Test
$AGYP ~ Chart oversold (RSI 44) #Oil #Gas >>
Allied Energy Corporation (OTC: AGYP)
https://alliedengycorp.com/
$BLEG Acquires Patent NFL Training Equipment
The Quickness is a sports training assembly designed to help training from a more real-life scenario with the element of surprise. The training assembly includes a plurality of remote targets. Each of the remote targets is positionable on a training field and each of the remote targets respectively emits a visual alert when the respective remote target is turned on. In this way the respective remote target is established as the desired target for the athlete to strike. A base target is positionable on the training field and the base target emits a visual alert when the base target is turned on thereby establishing the base target as the desired target for the athlete to strike. Moreover, the base target is in electrical communication with each of the remote targets in a random sequence. A plurality of balls is provided and each of the base and remote targets is mounted on a respective on of the balls. Moreover, each of the balls is biased to vertically orient the remote and base targets for striking.
$GTCH To protect the original patent’s concepts focusing on semiconductor wafers mounting on vertical and horizontal planes. The original invention design presents a new way to design and manufacture larger size integrated circuits (ICs) to fit advanced analog, digital and mixed IC types on a silicon wafer. The technology that was subject to the patent sought to enable the advanced microchip design and manufacturing within significantly less space which can be a major factor for IC’s manufacturing, performance and cost. It is thought that the invention can be a game changer particularly for integrated circuits that require vast amount of silicon space like memories, CPU, GPU and AI. The Company’s 3D microchip patent was filed on March 5, 2019, and was granted as of December 1, 2020 by the USPTO; U.S. Patent No. 10,854,763. The continuation application, assigned number 17102928, was filed on November 24, 2020. The Company’s intent in filing the continuation is to broaden the protection of its main IP concepts. It is GBT’s goal to further develop advancements in this domain through the use of the 3D, multidimensional design, utilizing more space on the silicon wafer, enabling manufacturing of larger ICs, with higher performance, lower power consumption and cheaper. This technology can be particularly advantageous for fabless design houses to design advanced microchips with much lower cost.
iQSTEL, Inc. announced entering into an exclusive, non-binding letter-of-intent (LOI) whereby, for the purposes of an intended acquisition, the company will conduct due diligence on 2,300 miles of fiber-optic network located in America.
iQSTEL has been in discussions with the target acquisition over the past two years first announcing a potential partnership in May of 2021.
The acquisition would accelerate iQSTEL’s entry into the 5G marketplace, expected to reach $700 billion by 2025.
Following a 90-day due-diligence period, iQSTEL is expected to make an offer for the acquisition of 100% of the capital stock of the company that owns the fiber-optic network.
https://finance.yahoo.com/news/iqst-iqstel-announces-loi-could-142500395.html
$PBIO Pressure BioSciences Discusses Launch of Early Access Program for Ultra Shear Technology for the Processing of Nanoemulsions with The Stock Day Podcast
https://www.newsfilecorp.com/release/126142
$PVSP Updated Trader's Cheat Sheet https://www.barchart.com/stocks/quotes/PVSP/cheat-sheet
$GTCH Artificial intelligence (AI) is becoming ubiquitous and increasingly indispensable in many sectors, so it is perhaps unsurprising that it is seeing more and more application for military purposes. A report published by Vantage Market Research finds that the global market for AI in Military is projected to grow from $6.62 billion USD in 2021 to $13.71 billion by 2028, while registering a compound annual growth rate (CAGR) of 12.9 percent in the forecast period 2022-28. The report cites AI's use in cybersecurity, communications, threat detection, and more as important market drivers. In a recent interview with Investorideas.com, Danny Rittman, the CTO of GBT Technologies Inc. (OTC Pink: GTCH), highlighted the use of AI in analytics and detection as a key to the market's growth.
https://www.barrons.com/articles/the-ai-eye-podcast-gbt-s-cto-discusses-ai-application-in-military-market-01651579670?mod=md_stockoverview_news
$AITX AITX's Subsidiary Robotic Assistance Devices to Host Public Safety Event in New York City June 30, 2022
https://www.globenewswire.com/news-release/2022/05/31/2453303/0/en/AITX-s-Subsidiary-Robotic-Assistance-Devices-to-Host-Public-Safety-Event-in-New-York-City-June-30-2022.html
$PVSP Artizen On Instagram:
https://www.instagram.com/reel/CVRjKSOBw4c/
$AGYP put this undervalued oil play on strong watch!
https://alliedengycorp.com/
$GTCH Security Details https://www.otcmarkets.com/stock/GTCH/security
$GTCH GBT Roadmaps The Development of a Wearable Version for Its qTerm Device https://newsfilter.io/a/87d4022ff93dfa7e6a3f5489e6d3eb42
Clickstream Corp - CLIS Got Featured on PubCo Insight Today.
"Not much in the news from Clickstream either as it closed its successful beta launch of the Nifter NFT music platform. Nifter will be providing details of its full launch via its Discord server at some point in the near future. Until then, Clickstream is working hard to continue adding enhancements to its HeyPal social language learning app, as well as preparing for the launch of its Wowee World children’s education app." - PubCo Insight Reports.
https://pubcoinsight.com/2022/05/26/stock-market-research/
$IVDN: Innovative Designs: Game-Changing House Wrap Technology
Red Chip video CEO interview here:
$SWISF EXCLUSIVE INTERVIEW w/CEO: ALAIN GHIAI - SEKUR Private Data
$AGYP on alert! Rush of buying right out of the gate on this low float oil play trading under .20! Recently announced large share reduction and oil production >>
Allied Energy Corporation Continues Selling Numerous loads of Oil From Their Producing Wells Throughout April
https://www.mcapmediawire.com/allied-energy-corporation-continues-selling-numerous-loads-of-oil-from-their-producing-wells-throughout-april/
Allied Energy Execute Documents To Retire 2,480,000 Common Shares From Public Float AGYP
https://www.globenewswire.com/news-release/2022/05/05/2437103/0/en/Allied-Energy-Execute-Documents-To-Retire-2-480-000-Common-Shares-From-Public-Float.html
$PVSP CEOs Presented at the Emerging Growth Conference on April 27; Register Now https://finance.yahoo.com/news/ceos-presenting-emerging-growth-conference-110000306.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
$BLEG Branded Legacy, Inc. To Introduce New Delta 9 Blend
THC-0/Delta-8 Blend Gummies Sell Out Again
ORLANDO, FL, May 25, 2022 (GLOBE NEWSWIRE) -- Branded Legacy, Inc. (OTCQB: BLEG), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages, along with an array of CBD topicals and tinctures is pleased to announce a new blend of gummies on the horizon.
In an industry where everything is changing rapidly it is incredibly important to stay ahead of the curve and capitalize on exciting new products. Delta 9 is just that. It allows us to stay under the legal limit but gives our customers some THC to provide the relief they are looking for. Delta 9 has been used in treatment for calmness, muscle relaxation, stress relief, improving moods and other benefits. The Delta strain continues to set the bar high for mind/body recovery as well. We’ll be looking to blend delta 9 with delta 8 so that we provide a stable lower dose product.
These new products will come in multiple flavors starting with green apple and mango. We’ll also be looking to add tropical drink flavors such as mimosa, strawberry daiquiri, and pina colada! Delta 9 blend will also be available in tincture form and cartridge form shortly after.
The Company’s new THC-0/Delta-8 gummies continue to thrive. Company has sold out of both flavors again and have placed its biggest order to date to ensure all customers shelves stay stocked. Partnership with All In Extracts, LLC has helped propel gummy sales by more than 50% with its THC-0/Delta-8 blend.
Brandon White, President of Branded Legacy, Inc., stated, “We as a company will continue to evolve and differentiate ourselves from other brands. This new Delta-9/Delta-8 blend is just another avenue in that goal. We’ve seen great success with our THC-0/Delta-8 Blend and we are excited to add this new blend to our growing list of products. Most importantly we are listening to what our customers are looking for in a CBD product and are laser focused on delivering that product to the masses."
$PVSP Twitter status update: https://twitter.com/PervasipC
$RFHRF RFHRF: Renforth Resources Continues to Advance Surimeau, an early stage polymetallic (Ni-Cu-Co-Zn) project; progress is being reported steadily on a monthly basis.
https://finance.yahoo.com/news/rfhrf-renforth-resources-continues-advance-101800808.html
$AAGC Hollywood Star Cuts Accelerates Its Rapid Growth
https://www.globenewswire.com/news-release/2022/05/25/2450438/0/en/Hollywood-Star-Cuts-Accelerates-Its-Rapid-Growth.html
Followers
|
1398
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
197571
|
Created
|
06/19/07
|
Type
|
Free
|
Moderator vantillian | |||
Assistants Daytrader1 Golden Cross Murray RedSox04 |
Historic Amazing Calls From This Board
CIRT $.0004 - $.012 $2,000%+
TDWV $.003 - $.065 2000%+
IAHL $.02 - $.14 700%
SHMM $.0021 - $.012 571%
BNEZ $.001 - $.0055 450%
LNGT $.002 - $.009 350%
MWPE $.0004 - $.0017 325%
PRSU $.0019 - $.0049 258%
ASVN $.0004 - $.0013 225%
SKGT $.0002 - $.0006 200%
AZTC $.006 - $.0018 200%
SPVG $.0011 - $.0032 190%
NSHV $.016 - $.041 157%
ICBM $.0006 - $.0012 100%
MCCI $.001 - $.002 100%
FTCH - .0040 to .18
DIOM - .014 to .051
AMHD - .0011 to .0034
LLEG - .0028 to .0040
VRED - .0050 to .045
SGGC - .0018 to .0065
RVGD - .0020 to .017
EWDI - called at .0001 when you could still buy .0001 (and THAT'simportant!)
MHGI - called at .0003, went to .0008.
CGGP - *YET AGAIN!* - called at .0015, went to .0045
GWOW - 1000%+ gainer - called at .02
BLTA - called at .08...went to .16+
CGGP *again* - called at .0017, went to .0035
UWRL - called at .0006, went to .0012
VSTR - called at .03, went to .08
PNHI - called at .02 and ran to .12
TOFS - called at .02 - hit .075
METP / ITRM - called at .01 -- went to .095
EWDI - called at .0017 -- went to .0037
CGGP - from .0030 to .02
DLAV .0007-.0008 went up 2857%!!!
IACH in at .0014-.002 at .008!!!
LDSR called at .0006 - van was pounding the table on this repeatedly under .001
ADAC called at .025 went to .098
SODE alerted .15 went over .30 could see dollar+
NBDR alerted .05 went over .10 could see much much more
PACV alerted .0075 has seen .032 so far could see big silver
IMTV alerted .0009 has hit .0030 so far looking for MUCH MORE
SAGD alerted .008ish watch what she gonna do!!!
CZNI formerly UHLN alerted .0007 high of .0033 so far
NOUV called at .0003 and went to .0020
MUST READ EDUCATIONAL STUFF |
If you are an avid follower then stand up and be counted as an official BEAN COUNTER! Just PM one of the mods or publicly post these O SO MAGIC WORDS: "Beans unite!"
...and we'll add your name to this prestigious list of BEANCOUNTERS (latest additions at bottom):
s
Giving Back!!! Charitable Opportunities!!!
Here are two charities that are close to van man's heart!!! Check em out and feel free to PM me if you have questions about these good peoples!!!
Every Child In A Loving Family Website | Facebook These good peeps made van man a daddy forever! |
Join in with your picks!!
MAKE SURE AND SIGN UP FOR OUR E-MAIL LIST! WE ONLY SEND OUR BEST PICKS AND PLAYS OUT ON IT.
Posts Today
|
1
|
Posts (Total)
|
197571
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |